Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience.

Future oncology (London, England) - 1 Jan 2024

Sbrana Andrea, Cappelli Sabrina, Petrini Iacopo, Bernardini Laura, Massa Valentina, Carrozzi Laura, Chella Antonio

Abstract excerpt

Aim: We retrospectively evaluated the effect of dabrafenib/trametinib combination in patients with BRAF-mutated non-small-cell lung cancer (NSCLC) treated in a single center from 2017 to 2022.Patients: The response and safety data of 42 patients (27 treated in first-line and 15 as second/subsequent lines) were analyzed.Results: The objective response was 73.8%, with no differences between patients undergoing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Oximes

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 38709118
DOI: 10.1080/14796694.2024.2340898
PMCID: PMC11486151

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience.PMID 38709118Read ↗

Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAFV600E mutation-positive metastatic non-small cell lung cancerSemantic proximity Read ↗

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.Semantic proximity Read ↗

Dabrafenib and trametinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.Semantic proximity Read ↗

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.Semantic proximity Read ↗

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Semantic proximity Read ↗

Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.Semantic proximity Read ↗

Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus TrametinibSemantic proximity Read ↗

RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.Semantic proximity Read ↗

Dacomitinib as first-line treatment for patients with EGFR-mutant non-small- cell lung cancer: Real-world data and InsightsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.